Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
published : This year entities : Amneal pharmaceuticals, inc. save search
Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine
Published: 2024-04-16 (Crawled : 14:00) - biospace.com/
AMRX | $5.345 -2.11% 310K
|
Health Technology
|
| O: -1.08%
H: 1.09%
C: -0.55%
rtu first
Amneal to Report First Quarter 2024 Results on May 3, 2024
Published: 2024-04-10 (Crawled : 13:00) - biospace.com/
AMRX | $5.345 -2.11% 310K
|
Health Technology
|
| O: -0.52%
H: 3.86%
C: 0.0%
first report results
Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension
Published: 2024-03-25 (Crawled : 23:00) - biospace.com/
AMRX | $5.345 -2.11% 310K
|
Health Technology
|
| O: 0.0%
H: 0.33%
C: -2.64%
fda approval
Amneal Enters into Exclusive European Licensing Agreement with Zambon Biotech for IPX203
Published: 2024-02-27 (Crawled : 14:00) - biospace.com/
AMRX | $5.345 -2.11% 310K
|
Health Technology
|
| O: -1.89%
H: 1.75%
C: 0.0%
ipx203 biotech agreement
Amneal to Participate at Upcoming Investor Conference
Published: 2024-02-13 (Crawled : 13:30) - biospace.com/
AMRX | $5.345 -2.11% 310K
|
Health Technology
|
| O: -3.84%
H: 2.57%
C: -0.45%
conference
Amneal Announces Complete Response Resubmission for IPX203 New Drug Application
Published: 2024-02-08 (Crawled : 21:00) - globenewswire.com
AMRX | $5.345 -2.11% 310K
|
Health Technology
|
| O: 0.18%
H: 1.83%
C: 1.83%
ipx203 drug resubmission application response
I-Mab Signs Agreement to Divest its Assets and Business Operations in China
Published: 2024-02-07 (Crawled : 11:00) - prnewswire.com
AMRX | $5.345 -2.11% 310K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -4.29%
IMAB | $1.81 63K
|
Health Technology
|
| O: 2.49%
H: 0.97%
C: -2.91%
business agreement china
Deb Autor, Former FDA Deputy Commissioner, Appointed CEO of Healthcare Innovation Catalysts
Published: 2024-02-01 (Crawled : 13:00) - biospace.com/
AMRX | $5.345 -2.11% 310K
|
Health Technology
|
| O: 2.8%
H: 0.55%
C: 0.18%
fda ceo innovation
Knight Therapeutics Enters into Exclusive License Agreement with Amneal Pharmaceuticals for IPX203
Published: 2024-01-25 (Crawled : 12:30) - globenewswire.com
AMRX | $5.345 -2.11% 310K
|
Health Technology
|
| O: 1.57%
H: 0.73%
C: -0.82%
ipx203 license pharmaceuticals therapeutics agreement
Amneal Launches Complex Generic Fluorometholone Ophthalmic Suspension
Published: 2024-01-10 (Crawled : 14:30) - biospace.com/
AMRX | $5.345 -2.11% 310K
|
Health Technology
|
| O: 0.0%
H: 0.7%
C: -3.16%
Gainers vs Losers
| 68% | 32% |
Top 10 Gainers
AGBA | $1.05 162.5% 100M
|
Finance
ISPC | $0.4621 116.95% 15M
|
Professional, Scientific, and T...
INVO | $1.515 99.34% 4.3M
|
Health Technology
BPTH | $5.62 73.46% 75M
|
Health Technology
TIRX | $0.8231 69.78% 54M
|
XPON | $2.63 36.27% 8.4M
|
PRTG | $0.299 35.17% 120K
|
Mining, Quarrying, and Oil and ...
VTNR S | $1.26 28.68% 9.1M
|
Industrial Services
SWVL | $9.64 27.35% 200K
|
n/a
DFLI A | $0.7726 25.52% 4.3M
|
Your saved searches
Save your searches and get alerts when important news are released.